Irritable Bowel Syndrome, PA:  A new clinical study is being conducted for participants that have IBS with constipation.  Forest Laboratories is testing a new drug linaclotide to determine its safety and efficacy for IBS-C.  The study design includes a double blind, placebo controlled groups.  The trail participants will receive an oral dosage of linaclotide for 12 weeks followed by a 4 week withdrawal period.  Estimated enrollment in the study is 800.  The completion date for the study is anticipated to be in July 2010.

Irritable Bowel is a functional medical problem that effects 20 % of the U.S. population.  The characteristics of IBS may include diarrhea, constipation (or both), abdominal pain, gas, and bloating.  Because of these symptoms the quality of life of sufferers is often affected.  At this point the medical community has not determined exactly what causes Irritable Bowel Syndrome.

If you are interested in receiving more information about Irritable Bowel Syndrome you are invited visit www.MyIBSRelief.com.